The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Marine Polymer Technologies sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
Marine Polymer Technologies is a medical device company that researches, develops, and markets technologies for haemostasis and wound healing. The company has its proprietary technology platform Poly-N-Acetyl Glucosamine, which is effective in the treatment of diabetic wounds, bleeding control and vascular catheterization haemostasis. The company markets its products under the brands, Syvek, Talymed, and mrdh. The company sells its products in the US, Europe, and Korea. MPT is headquartered in Tewksbury, Massachusetts, the US.
The key metrics of Marine Polymer Technologies related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:
As Marine Polymer Technologies is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Marine Polymer Technologies.
For a detailed understanding of the performance of Marine Polymer Technologies, buy the report here.